More Recce Pharmaceuticals Ltd. news
Recce Pharmaceuticals Ltd.ASX: RCE

Ethics Approval to Start Phase 1 Intravenous Clinical Trial

Oct 24, 2021 at 11:37 PM EDT · Issued by Recce Pharmaceuticals Ltd.

Filed with ASX · Oct 24, 2021 at 11:37 PM EDT

On 6ix: 6ix.com/news/ethics-approval-to-start-phase-1-intravenous-clinical-trial

Recce Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Recce Pharmaceuticals Ltd. on 6ix

Story so far

  • HREC Approval to Start Phase I/II Burns Wound StudyOct 16, 2020

Earlier from Recce Pharmaceuticals

  • Reinstatement to Official QuotationOct 12, 2021
  • Court Orders GrantedOct 11, 2021
  • Suspension from Official QuotationOct 11, 2021
  • Trading haltOct 8, 2021
  • R327 Phase I Clinical Trial Registered on ANZCTRSep 30, 2021

Later from Recce Pharmaceuticals

  • Appendix 4C and Activity ReportOct 29, 2021
  • Update on Phase I/II Clinical Trial for Burn Wound InfectionDec 6, 2021
  • Patients to be Dosed in Ph 1 IV Clinical Trial of R327Dec 14, 2021
  • Positive Safety Data from Phase 1 Clinical TrialJan 6, 2022
  • Positive Safety Data from Second Cohort of PI Clinical TrialJan 18, 2022
All Recce Pharmaceuticals news releases↗

Follow Recce Pharmaceuticals into a list and get an email when it puts out news.

Follow Recce Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer